Risk of fatal pulmonary embolism with oral contraceptives
- PMID: 10902616
- DOI: 10.1016/S0140-6736(00)02369-2
Risk of fatal pulmonary embolism with oral contraceptives
Abstract
PIP: This commentary addresses the New Zealand study (case report) of a fatal pulmonary embolism (PE) associated with oral contraceptive (OC) use by L. Parkin and colleagues. The study significantly adds to the knowledge on the relationship between fatal PE and OC use, because most of the evidence up to now has related to nonfatal venous thromboembolic events (VTE). Several areas of the study, however, are criticized. These include the method used, definition, and the adjustment of data. However, these criticisms have been offered explanations in this commentary. It is noted that data from the study indicated that OCs containing desogestrel or gestodene are associated with higher risks of fatal PE than are those containing levonorgestrel. This is consistent with most previous studies comparing the effects of second-generation progestogens on VTE. Overall, data support previous pragmatic recommendations that second-generation pills, which contain levonorgestrel, are the combined OCs of choice.
Comment on
-
Oral contraceptives and fatal pulmonary embolism.Lancet. 2000 Jun 17;355(9221):2133-4. doi: 10.1016/S0140-6736(00)02382-5. Lancet. 2000. PMID: 10902629
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
